MX2009012315A - Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip). - Google Patents

Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip).

Info

Publication number
MX2009012315A
MX2009012315A MX2009012315A MX2009012315A MX2009012315A MX 2009012315 A MX2009012315 A MX 2009012315A MX 2009012315 A MX2009012315 A MX 2009012315A MX 2009012315 A MX2009012315 A MX 2009012315A MX 2009012315 A MX2009012315 A MX 2009012315A
Authority
MX
Mexico
Prior art keywords
animal
sirna
small interfering
memory formation
gene
Prior art date
Application number
MX2009012315A
Other languages
English (en)
Inventor
Timothy P Tully
Rusiko Bourtchouladze
Roderick E M Scott
Marco Peters
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of MX2009012315A publication Critical patent/MX2009012315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para identificar un gen o producto de gen relacionado con la formación de memoria dependiente de transcripción en un animal que comprende los pasos de: (a) administrar a dicho animal suficiente ARN (ARNip) específico para un gen para inhibir dicha función del gen; (b) entrenar dicho animal bajo condiciones suficientes para inducir la formación de memoria dependiente de transcripción en un animal no tratado normal; y (c) determinar el nivel de formación de memoria dependiente de transcripción inducido por el entrenamiento de dicho animal tratado. La presente invención proporciona métodos para utilizar ARNs (ARNip) de interferencia pequeña en el hipocampo para identificar los genes y el producto del gen cuya inhibición afecta la memoria a largo plazo temporal y contextual (LTM); sin embargo, no la memoria acorto plazo (STM).
MX2009012315A 2007-05-15 2008-05-15 Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip). MX2009012315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93816507P 2007-05-15 2007-05-15
PCT/US2008/063806 WO2008144455A1 (en) 2007-05-15 2008-05-15 Methods of identifying genes involved in memory formation using small interfering rna(sirna)

Publications (1)

Publication Number Publication Date
MX2009012315A true MX2009012315A (es) 2009-12-03

Family

ID=40122146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012315A MX2009012315A (es) 2007-05-15 2008-05-15 Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip).

Country Status (11)

Country Link
US (1) US20090053140A1 (es)
EP (1) EP2152275A4 (es)
JP (1) JP2010527243A (es)
KR (1) KR20100017422A (es)
CN (1) CN102014928A (es)
AU (1) AU2008254907A1 (es)
BR (1) BRPI0811623A2 (es)
CA (1) CA2684879A1 (es)
IL (1) IL202090A0 (es)
MX (1) MX2009012315A (es)
WO (1) WO2008144455A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104583217B (zh) 2012-06-18 2017-11-17 达特神经科学(开曼)有限公司 取代的噻吩稠合的和呋喃稠合的唑并嘧啶‑5‑(6h)‑酮化合物
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
CA2895287A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CN103736102A (zh) * 2013-11-14 2014-04-23 黄兵 可用于治疗银屑病的小rna及其衍生物和药物制剂
WO2015140799A1 (en) * 2014-03-18 2015-09-24 Carmel-Haifa University Economic Corp. Ltd Methods for improving cognitive function via modulation of quinone reductase 2
HRP20212035T1 (hr) 2014-04-23 2022-04-01 Dart Neuroscience Llc Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
WO2016073420A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
EP3215508A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
EP3652180B1 (en) 2017-07-12 2023-11-29 Dart NeuroScience, LLC Substituted benzoxazole and benzofuran compounds as pde7 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
US11365191B2 (en) 2018-02-28 2022-06-21 Dart Neuroscience, Llc Substituted cyclohexyl compounds as NOP inhibiiors
CN114432450B (zh) * 2021-11-19 2023-05-23 北京市创伤骨科研究所 Creb1抑制剂666-15在制备治疗骨关节炎药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005256B1 (en) * 1999-03-10 2006-02-28 Cold Spring Harbor Laboratory Gene chip technology for determining memory genes
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
PT1540335E (pt) * 2002-08-19 2010-06-23 Helicon Therapeutics Inc Métodos de identificação de estimuladores cognitivos
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
WO2005104836A2 (en) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Drosophila models for diseases affecting learning and memory
CA2605574A1 (en) * 2004-04-20 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US20070161592A1 (en) * 2005-09-14 2007-07-12 Min Zhuo Method of treating fear
EP2377530A3 (en) * 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition

Also Published As

Publication number Publication date
CN102014928A (zh) 2011-04-13
EP2152275A4 (en) 2011-08-03
KR20100017422A (ko) 2010-02-16
IL202090A0 (en) 2010-06-16
EP2152275A1 (en) 2010-02-17
BRPI0811623A2 (pt) 2014-11-11
WO2008144455A1 (en) 2008-11-27
AU2008254907A1 (en) 2008-11-27
JP2010527243A (ja) 2010-08-12
CA2684879A1 (en) 2008-11-27
US20090053140A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MX2009012315A (es) Metodos de identificacion de genes involucrados en la formacion de memoria utilizando arn pequeño de interferencia (arnip).
Wei et al. Dicer-like 3 produces transposable element-associated 24-nt siRNAs that control agricultural traits in rice
Xie et al. LncRNA TRG-AS1 promotes glioblastoma cell proliferation by competitively binding with miR-877-5p to regulate SUZ12 expression
Wang et al. In vivo knockdown of hippocampal miR‐132 expression impairs memory acquisition of trace fear conditioning
WO2009114681A3 (en) Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
WO2010111471A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
Bai et al. Sodium butyrate induces differentiation of gastric cancer cells to intestinal cells via the PTEN/phosphoinositide 3‐kinase pathway
WO2005040379A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK2260301T3 (da) Gensignaturer
WO2011150241A3 (en) Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression
WO2004111190A3 (en) IN VIVO HIGH THROUGHPUT SELECTION OF EFFECTIVE RNAi PROBES
WO2005112636A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES
Zhang et al. MiR‐107 down‐regulates SIAH1 expression in human breast cancer cells and silencing of miR‐107 inhibits tumor growth in a nude mouse model of triple‐negative breast cancer
Oktyabri et al. EED regulates epithelial–mesenchymal transition of cancer cells induced by TGF-β
WO2010107955A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
MX2009002462A (es) Siarn y metodos de manufactura del mismo.
Bu et al. MicroRNA‑203 inhibits malignant melanoma cell migration by targeting versican Retraction in/10.3892/etm. 2023.12308
Liu et al. Overexpression of circular RNA circ‐CDC45 facilitates glioma cell progression by sponging miR‐516b and miR‐527 and predicts an adverse prognosis
Patella et al. MiR‐492 impairs the angiogenic potential of endothelial cells
WO2005045037A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012091496A3 (en) siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
CA2810119C (en) Clec14a inhibitors
WO2009112270A3 (de) Verfahren zur erzeugung einer breitband-resistenz gegenüber pilzen in transgenen pflanzen
WO2005045040A3 (en) RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID /siNA)
WO2010111497A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal